Freezing of Gait - Clinical Outcomes Assessment

NCT ID: NCT06519279

Last Updated: 2025-01-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To develop a reliable and accurate clinician-reported outcome (ClinRO) measure (against a new and precise definition) and patient reported outcome (PRO) for use by clinicians and researchers to quantify the severity of Freezing of Gait (FOG).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PD - Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Freezing Of Gait Patients

15 patients with Parkinson disease with freezing of gait (group) in ON \& OFF states

Opals

Intervention Type DEVICE

Five Oplas sensors were strategically placed on participants: one on each shin, one on each foot, and one on the lower back.

Axivity

Intervention Type DEVICE

At the end of the first session, participants with FOG, will be fitted with an Axivity monitor. This is wearable sensor that will be attached to the participant's lower back (lumbar vertebrae 4-5) with hypoallergic medical tape by the researcher, and will be worn continuously for seven days.

The Axivity monitor is a small (23 x 32.5 x 8.9 mm) and lightweight (11g) device that measures mobility via a tri-axial accelerometer and gyroscope and stores this data onboard, no GPS or other localization options are possible with this monitor. Participants will be given following guidelines concerning the use:

The sensor is to be worn continuously during the seven-day period, i.e. also while sleeping and showering.

The sensor is waterproof and can be worn during showering.

Non Freezing Of Gait Patients

5 patients with Parkinson disease without freezing of gait (cohort) in ON \& OFF states

Opals

Intervention Type DEVICE

Five Oplas sensors were strategically placed on participants: one on each shin, one on each foot, and one on the lower back.

Axivity

Intervention Type DEVICE

At the end of the first session, participants with FOG, will be fitted with an Axivity monitor. This is wearable sensor that will be attached to the participant's lower back (lumbar vertebrae 4-5) with hypoallergic medical tape by the researcher, and will be worn continuously for seven days.

The Axivity monitor is a small (23 x 32.5 x 8.9 mm) and lightweight (11g) device that measures mobility via a tri-axial accelerometer and gyroscope and stores this data onboard, no GPS or other localization options are possible with this monitor. Participants will be given following guidelines concerning the use:

The sensor is to be worn continuously during the seven-day period, i.e. also while sleeping and showering.

The sensor is waterproof and can be worn during showering.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Opals

Five Oplas sensors were strategically placed on participants: one on each shin, one on each foot, and one on the lower back.

Intervention Type DEVICE

Axivity

At the end of the first session, participants with FOG, will be fitted with an Axivity monitor. This is wearable sensor that will be attached to the participant's lower back (lumbar vertebrae 4-5) with hypoallergic medical tape by the researcher, and will be worn continuously for seven days.

The Axivity monitor is a small (23 x 32.5 x 8.9 mm) and lightweight (11g) device that measures mobility via a tri-axial accelerometer and gyroscope and stores this data onboard, no GPS or other localization options are possible with this monitor. Participants will be given following guidelines concerning the use:

The sensor is to be worn continuously during the seven-day period, i.e. also while sleeping and showering.

The sensor is waterproof and can be worn during showering.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of idiopathic Parkinson's disease (PD) made by a neurologist according to the Movement Disorders Society guidelines;
2. Able to walk independently for a distance of 10 meters, without walking aid;
3. Absence of a Deep Brain Stimulator;
4. Stable PD treatment in the 4 weeks prior to participation that is not expected to change in the course of the study.
5. For patients with FOG: a score of ≥ 1 on the New Freezing Of Gait Questionnaire (NFOG-Q).

Exclusion Criteria

1. Occurrence of any of the following within 3 months prior to informed consent: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), implantation of a cardiac resynchronization therapy device (CRTD), active treatment for cancer or other malignant disease, uncontrolled congestive heart disease (NYHA class \>3), acute psychosis or major psychiatric disorders or continued substance abuse, other neurological (than PD) or orthopaedic impairment that significantly impacts on gait.
2. Unwilling to temporarily delay the morning anti-Parkinsonian medication.
3. Preganacy and
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

KU Leuven

OTHER

Sponsor Role collaborator

Oregon Health and Science University

OTHER

Sponsor Role collaborator

University of Sydney

OTHER

Sponsor Role collaborator

Radbound University Medical Center

UNKNOWN

Sponsor Role collaborator

University of Waterloo

OTHER

Sponsor Role collaborator

Emory University

OTHER

Sponsor Role collaborator

University of Rochester

OTHER

Sponsor Role collaborator

Tel-Aviv Sourasky Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tel Aviv Saurasky Medical Center

Tel Aviv, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Omri Batori, B.sc

Role: CONTACT

+972546670256

Jeffery Hausdorff, Professor

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

omri Batori, B.sc

Role: primary

+972546670256

Shahar Siman Toc, B.sc

Role: backup

+972526736689

Jeffery Hausdorff, Proffesor

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0608-23-TLV

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Percept Transitions in FOG and PD
NCT06848205 NOT_YET_RECRUITING NA